

Pei-Chuan Ho¹, Boon Lead Tee², Clara Li³, Yian Gu⁴, Jennifer Yokoyama², Dolly Reyes-Dumeyer⁴, Kelley Faber⁵, Wan-Ping Lee¹, Yeunjoo Song⁶, Marian Tzuang², Badri Vardarajan⁴, Hyun-Sik Yang⁷, Yun-Beom Choi⁸, Howard Feldman⁹, Joshua Grill¹⁰, Victor Henderson¹¹, Ging-Yuek Hsiung¹², Richard Mayeux⁴, Howard Rosen², Rohit Varma¹³, Tatiana Foroud⁵, Walter Kukull¹⁴, Guerry Peavy⁷, Haeok Lee¹⁵, W. Haung Yu¹⁶, Helena Chui¹⁷, Gyungah Jun¹⁸, Van Park², Tiffany Chow¹, Li-San Wang¹, and The Asian Cohort for Alzheimer's Disease Study

¹University of Pennsylvania; ²UC San Francisco; ³Icahn School of Medicine at Mount Sinai; ⁴Columbia University; ⁵Indiana University; ⁶Case Western Reserve University; ⁷Brigham and Women's Hospital; ⁸Englewood Health; ⁹UC San Diego; ¹⁰UC Irvine; ¹¹Stanford University; ¹²University of British Columbia; ¹³Southern California Eye Institute; ¹⁴Washington University in St. Louis; ¹⁵New York University; ¹⁶University of Toronto; ¹⁷University of Southern California; ¹⁸Boston University

ACAD Website




Introduction

Asian Americans and Canadians (ASACs) are the fastest growing minority group in the US and Canada, but they are under-representative in AD research. ACAD aims to recruit >5,000 ASACs in 2023-2028, using culturally appropriate, community-based approaches to address the knowledge gap.

Population in focus :


- Chinese
- Korean
- Vietnamese

ACAD Recruitment Sites




ACAD leverages national AD research resources and collaborates with AD experts and community partners

We have assembled a team of scientists, clinicians, and community partners with a history of collaboration and expertise in AD research, human genetics, and Asian community outreach.



ACAD is the 1st large dementia genetics cohort for AD among Asian Americans/Canadians


Recruitment Progress as of June 2026




Participant Characteristics (N = 1,517*)

- Average age = 73.6
- 32% men and 68% women

A. Ethnicity Distribution



B. Highest Degree Attained



Thoughts from Community Advisory Board Members



"This is an unprecedented and largest scale study attempting to solve the mystery of AD in the Asian communities. The cooperation among American and Canadian institutions and researches is generating positive outcome."

Joseph Wong, C.M., M.D., D.Sc.(Hon.)
Yee Hong Centre for Geriatric Care

"Grateful for ACAD in creating a voice of Asians in US and Canada to fight against AD that will positively affect our next generations. ACAD is necessary for the development of culturally appropriate prevention, treatment and future cure for AD in Asians."

David Choi
YE Media Group



ACAD Protocol Highlights

- Early life experiences
- Physical activities
- Social network
- Cognitive battery
- Neurological assessment
- Immigration experiences
- Diet & sleep
- Medical history
- Functional assessment
- Plasma biomarker

Data in Progress

- SNP array data
- WGS (many thanks to ADSP-FUS!)
- Plasma biomarker: A β 40/42, P-Tau 181/217, GFAP, NfL
- Proteomics (many thanks to NIH CRAD!)
- Phenotype

Next Steps

ACAD has built foundation materials to support sample collection and recruitment. ACAD will provide guidance for future studies to explore ASAC risk factors for AD and related dementias. In collaboration Alzheimer's Disease Genetics Consortium (ADGC) and Alzheimer's Disease Sequencing Project (ADSP), trans-ethnic insights from ACAD may identify potential novel, population-specific therapeutic pathways for AD.

ACAD Posters

July 12

- Poster #10316: Meta-analysis of GWAS and APOE in ACAD

July 13

- Poster #9154: Outreach and Recruitment in ACAD
- Poster #6747: CBRP in ACAD
- Poster #6809: Genetic Architecture of Plasma Biomarkers

July 15

- Poster #5683: ACAD Data Structure and Characteristics
- Poster #6717: Biomarkers from Dried Plasma Spot
- Poster #6804: Plasma Biomarker results from ACAD

Visit us!



Study overview



Clinical Protocol



Translation consideration



ACAD is supported by NIA R56-AG069130 and NIA U19-AG079774

Study Contact PI: Li-San Wang
lswang@penmedicine.upenn.edu